ING Groep NV Purchases 347 Shares of Catalent, Inc. (NYSE:CTLT)

ING Groep NV raised its stake in shares of Catalent, Inc. (NYSE:CTLT) by 3.2% in the 1st quarter, according to its most recent disclosure with the SEC. The firm owned 11,271 shares of the company’s stock after purchasing an additional 347 shares during the period. ING Groep NV’s holdings in Catalent were worth $1,187,000 as of its most recent SEC filing.

Several other institutional investors have also made changes to their positions in the company. BlackRock Inc. grew its stake in shares of Catalent by 5.3% during the first quarter. BlackRock Inc. now owns 13,988,761 shares of the company’s stock valued at $1,473,158,000 after buying an additional 701,908 shares during the last quarter. JPMorgan Chase & Co. grew its position in shares of Catalent by 0.6% during the 4th quarter. JPMorgan Chase & Co. now owns 5,332,447 shares of the company’s stock valued at $554,950,000 after acquiring an additional 31,411 shares during the period. Nuveen Asset Management LLC grew its position in shares of Catalent by 0.8% during the 4th quarter. Nuveen Asset Management LLC now owns 1,485,969 shares of the company’s stock valued at $154,645,000 after acquiring an additional 12,130 shares during the period. Norges Bank acquired a new stake in Catalent in the 4th quarter worth about $149,074,000. Finally, Bank of New York Mellon Corp lifted its stake in Catalent by 5.0% in the 4th quarter. Bank of New York Mellon Corp now owns 1,362,467 shares of the company’s stock worth $141,793,000 after purchasing an additional 64,787 shares in the last quarter. Institutional investors and hedge funds own 96.43% of the company’s stock.

CTLT has been the subject of several research reports. Argus boosted their price target on shares of Catalent from $130.00 to $140.00 and gave the stock a “buy” rating in a research note on Tuesday, March 2nd. They noted that the move was a valuation call. Zacks Investment Research upgraded shares of Catalent from a “hold” rating to a “buy” rating and set a $113.00 price target on the stock in a research report on Friday, June 4th. One equities research analyst has rated the stock with a hold rating and eight have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $123.78.

In related news, SVP Kay A. Schmidt sold 1,400 shares of the company’s stock in a transaction that occurred on Monday, March 22nd. The stock was sold at an average price of $105.77, for a total value of $148,078.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, SVP Steven L. Fasman sold 21,647 shares of the stock in a transaction that occurred on Thursday, March 18th. The stock was sold at an average price of $104.53, for a total value of $2,262,760.91. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 65,267 shares of company stock valued at $6,850,694. Company insiders own 1.00% of the company’s stock.

Shares of NYSE CTLT opened at $108.87 on Friday. The stock’s 50-day moving average is $106.62. The firm has a market cap of $18.55 billion, a P/E ratio of 36.66, a price-to-earnings-growth ratio of 1.84 and a beta of 1.45. The company has a current ratio of 2.44, a quick ratio of 1.97 and a debt-to-equity ratio of 0.85. Catalent, Inc. has a 12-month low of $67.97 and a 12-month high of $127.68.

Catalent (NYSE:CTLT) last announced its quarterly earnings results on Tuesday, May 4th. The company reported $0.82 earnings per share for the quarter, beating analysts’ consensus estimates of $0.74 by $0.08. The business had revenue of $1.05 billion for the quarter, compared to the consensus estimate of $994.28 million. Catalent had a net margin of 14.43% and a return on equity of 13.88%. Catalent’s revenue for the quarter was up 38.5% on a year-over-year basis. During the same period last year, the company posted $0.50 EPS. On average, research analysts predict that Catalent, Inc. will post 2.7 earnings per share for the current year.

Catalent Profile

Catalent, Inc, together with its subsidiaries, provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services.

Featured Story: Derivative

Institutional Ownership by Quarter for Catalent (NYSE:CTLT)

Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.